An Open-label,Phase I, Dose-escalation Trial to Evaluate the Safety, Tolerability, Maximum Tolerated Dose, Pharmacokinetic, and Pharmacodynamics of the Anti-FGFR2 Antibody Drug Conjugate BAY1187982 in Subjects With Advanced Solid Tumors Known to Express FGFR2.
Phase of Trial: Phase I
Latest Information Update: 14 Jul 2017
At a glance
- Drugs Abrutumab ixadotine (Primary)
- Indications Breast cancer; Male breast cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Bayer
- 05 Apr 2017 Results presented at the 108th Annual Meeting of the American Association for Cancer Research
- 30 Aug 2016 Status changed from active, no longer recruiting to discontinued.
- 23 Jun 2016 Status changed from recruiting to active, no longer recruiting.